Harandi H, Fallahtafti P, Karimi A, Hashemi S, Mahalleh M, Ashouri M
BMC Geriatr. 2024; 24(1):411.
PMID: 38720296
PMC: 11080142.
DOI: 10.1186/s12877-024-05006-0.
Ntanasis-Stathopoulos I, Filippatos C, Gavriatopoulou M, Malandrakis P, Eleutherakis-Papaiakovou E, Spiliopoulou V
Diseases. 2023; 11(3).
PMID: 37754319
PMC: 10529256.
DOI: 10.3390/diseases11030123.
Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F
Leukemia. 2023; 37(6):1175-1185.
PMID: 37142661
PMC: 10157596.
DOI: 10.1038/s41375-023-01920-1.
Magen H, Avigdor A, Nevo L, Fried S, Gibori A, Levin E
PLoS One. 2023; 18(5):e0284925.
PMID: 37126496
PMC: 10150979.
DOI: 10.1371/journal.pone.0284925.
Jani C, Schooley R, McKay R, Lippman S
Front Oncol. 2023; 13:1107384.
PMID: 36994197
PMC: 10040761.
DOI: 10.3389/fonc.2023.1107384.
Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis.
Chuleerarux N, Manothummetha K, Moonla C, Sanguankeo A, Kates O, Hirankarn N
Blood Adv. 2022; 6(24):6198-6207.
PMID: 36538342
PMC: 9561400.
DOI: 10.1182/bloodadvances.2022008530.
Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy.
Sahu T, Verma H, Lvks B
World J Virol. 2022; 11(4):204-207.
PMID: 36159615
PMC: 9372783.
DOI: 10.5501/wjv.v11.i4.204.
Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipients.
Nakazawa H, Sakai K, Sudo Y, Iwabuchi R, Sakai H, Nishina S
Transpl Immunol. 2022; 75:101713.
PMID: 36100196
PMC: 9465495.
DOI: 10.1016/j.trim.2022.101713.
SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies.
Terpos E, Fotiou D, Karalis V, Ntanasis-Stathopoulos I, Sklirou A, Gavriatopoulou M
Am J Hematol. 2022; 97(10):1300-1308.
PMID: 35871310
PMC: 9349831.
DOI: 10.1002/ajh.26669.
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review.
Piechotta V, Mellinghoff S, Hirsch C, Brinkmann A, Iannizzi C, Kreuzberger N
Blood Cancer J. 2022; 12(5):86.
PMID: 35641489
PMC: 9152308.
DOI: 10.1038/s41408-022-00684-8.
Correlation of SARS‑CoV‑2 to cancer: Carcinogenic or anticancer? (Review).
Li Y, Ren H, Cao J
Int J Oncol. 2022; 60(4).
PMID: 35234272
PMC: 8923649.
DOI: 10.3892/ijo.2022.5332.
Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma.
Terao T, Yamashita T, Fukumoto A, Kamura Y, Ikeda D, Kuzume A
Int J Hematol. 2022; 115(5):737-747.
PMID: 35190963
PMC: 8860256.
DOI: 10.1007/s12185-022-03300-4.
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
Greenberg R, Ruddy J, Boyarsky B, Werbel W, Garonzik-Wang J, Segev D
BMC Cancer. 2021; 21(1):1354.
PMID: 34961488
PMC: 8711688.
DOI: 10.1186/s12885-021-09097-5.
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study.
Sgherza N, Curci P, Rizzi R, Strafella V, Di Gennaro D, Vitucci A
Haematologica. 2021; 107(2):555-557.
PMID: 34732044
PMC: 8804555.
DOI: 10.3324/haematol.2021.279895.
Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis.
Schiller Salton N, Szwarcwort M, Tzoran I, Horowitz N, Zuckerman T, Horesh N
Am J Hematol. 2021; 96(12):E475-E478.
PMID: 34622495
PMC: 8646558.
DOI: 10.1002/ajh.26373.
Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?.
Mornese Pinna S, Lupia T, Scabini S, Vita D, De Benedetto I, Gaviraghi A
Int Immunopharmacol. 2021; 101(Pt A):108200.
PMID: 34607231
PMC: 8479899.
DOI: 10.1016/j.intimp.2021.108200.
Why are we vaccinating children against COVID-19?.
Kostoff R, Calina D, Kanduc D, Briggs M, Vlachoyiannopoulos P, Svistunov A
Toxicol Rep. 2021; 8:1665-1684.
PMID: 34540594
PMC: 8437699.
DOI: 10.1016/j.toxrep.2021.08.010.
Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study.
Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S, Malandrakis P
Blood Adv. 2021; 5(21):4398-4405.
PMID: 34529762
PMC: 8450138.
DOI: 10.1182/bloodadvances.2021005444.
Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
Gavriatopoulou M, Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, Briasoulis A, Gumeni S
Br J Haematol. 2021; 196(2):356-359.
PMID: 34528249
PMC: 8653218.
DOI: 10.1111/bjh.17841.
Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study.
Terpos E, Gavriatopoulou M, Fotiou D, Giatra C, Asimakopoulos I, Dimou M
Cancers (Basel). 2021; 13(17).
PMID: 34503290
PMC: 8430746.
DOI: 10.3390/cancers13174480.
